Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $114.60 and last traded at $114.7810, with a volume of 282797 shares trading hands. The stock had previously closed at $109.60.

Wall Street Analyst Weigh In

Several brokerages have commented on DNTH. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. HC Wainwright boosted their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $124.27.

Dianthus Therapeutics Stock Performance

The company has a market cap of $6.31 billion, a price-to-earnings ratio of -27.84 and a beta of 1.22. The company has a fifty day moving average of $96.76 and a two-hundred day moving average of $82.61.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Equities analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 31,249 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the transaction, the executive vice president owned 31,249 shares of the company’s stock, valued at $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Marino Garcia sold 166,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer directly owned 65,292 shares in the company, valued at $7,058,718.12. The trade was a 71.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 284,306 shares of company stock valued at $29,289,369. Corporate insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares in the last quarter. UBS Group AG increased its holdings in Dianthus Therapeutics by 342.6% in the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after purchasing an additional 469,547 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Dianthus Therapeutics by 1,275.3% in the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after buying an additional 441,156 shares during the period. SummitTX Capital L.P. boosted its stake in Dianthus Therapeutics by 13.8% during the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after acquiring an additional 12,118 shares in the last quarter. Finally, California State Teachers Retirement System raised its holdings in shares of Dianthus Therapeutics by 155.5% during the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock valued at $3,406,000 after purchasing an additional 24,697 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.